Navigation Links
Stopping Controversial Asthma Drugs Could Have Downside: Study
Date:8/27/2012

By Randy Dotinga
HealthDay Reporter

MONDAY, Aug. 27 (HealthDay News) -- It's OK for some patients with asthma to stick with a combination of medications instead of abandoning one because of concerns about complications, a new analysis of existing research suggests.

The U.S. Food and Drug Administration has warned that asthma patients who take both long-acting beta-agonist and inhaled corticosteroid medications should be cautious about using them together once their condition is under control.

Long-acting beta-agonists -- such as drugs known by the brand names Serevent, Foradil and Brovana -- could cause side effects, the FDA cautioned, as could combination drugs. For that reason, the agency suggested that patients consider going with inhaled corticosteroids alone.

However, the new analysis came to a different conclusion. "Adding a long-acting beta-agonist to an inhaled corticosteroid medication makes a lot of sense in a number of patients since you get better control of the disease," said Dr. Thomas Casale, chief of allergy and immunology at Creighton University, and lead author of the report.

The report was published online Aug. 27 in the journal Archives of Internal Medicine.

At issue is how to best treat adults and older children who suffer from moderate to severe asthma.

Inhaled corticosteroids, which come in inhalers and are known by brand names such as Azmacort and Flovent, are often prescribed by themselves to reduce wheezing and other symptoms. They're usually taken daily but don't relieve asthma attacks when they're occurring. (Short-acting beta-agonists, such as the drug albuterol, treat asthma attacks themselves.)

The newer long-acting beta-agonists are frequently used with inhaled corticosteroids. Some medications, sold under the brand names Symbicort and Advair, combine both types of drugs.

This latest analysis, which examined five studies involving patients ag
'/>"/>

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Stopping Blood Thinners Raises Stroke Risk for Patients With Irregular Heartbeat
2. Stopping and starting cancer cell cycle weakens and defeats multiple myeloma
3. Opioid receptors as a drug target for stopping obesity
4. U.S. Gives Green Light to Publish Controversial Bird Flu Research
5. Controversial vaccine trial should never have been run in India, researchers say
6. Supreme Court Backs Much of Controversial Health Reform Law
7. Rapid Asthma Treatment in ER May Prevent Admission
8. Some Schools Dont Let Kids Carry Asthma Inhalers
9. Secondhand smoke continues to vex children with asthma
10. Many Asthmatic Kids Harmed by Secondhand Smoke: Study
11. Seniors Undertreated for Asthma, and Many Skip Inhalers: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stopping Controversial Asthma Drugs Could Have Downside: Study
(Date:4/24/2014)... 4/24/14) Dartmouth has been awarded one of 30 ... as a Lead Academic Participating Site in its new ... recipients are a select groups of investigators charged with ... cooperative groups., The NCTN grant system reflects recommendations from ... streamlines operations to achieve four goals:, Faster ...
(Date:4/23/2014)... (MGH) investigators may lead to greater availability and acceptability ... use of fecal material from healthy donors to ... ( C. difficile ) bacteria. In their ... Infectious Diseases , the researchers report that use of ... was as successful in curing recurrent C. difficile ...
(Date:4/23/2014)... M.D., scientific director at the National Institute of Arthritis ... the 2014 recipient of the Ross Prize in Molecular ... Molecular Medicine . The award will be given ... Sciences in Manhattan, followed by scientific presentations by Dr. ... the National Institutes of Health. , The award, which ...
(Date:4/23/2014)... enzyme pathway that helps prevent new cells from receiving ... has been directly linked to cancer and other diseases. ... near the end of cell division, the enzyme Cdc14 ... DNA are fully repaired before the parent cell distributes ... helps safeguard against some of the most devastating genome ...
(Date:4/23/2014)... In science, "simple and accessible detection methods that ... the resolution of a single cell inside that ... chemical engineer Chang Lu. , In the Royal ... Lu has announced that he and his coworkers ... subcellular location of a protein ( Chem. Sci. ...
Breaking Medicine News(10 mins):Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2
... Revenue Up 16% ... Cellulite Product Launch Targeted for Late Q1 ... Company Updates Guidance for Full Year 2007, HAYWARD, Calif., Nov. 6 ... the aesthetic,industry, today reported its financial results for the third quarter ended,September 30, ...
... Organizations Rapidly Identify High-Risk Cases, Provide ... BIRMINGHAM, Ala., Nov. 6 The ... DST Health Solutions announced that 16,organizations have ... helps organizations rapidly identify at-risk patients for,care ...
... - Continued progress in both core business segments supports ... Corporation,(Nasdaq: VRNM ), a leading developer of technologies ... of high-performance specialty,enzymes, today reported financial results for the ... "We are very pleased with the progress the Company ...
... Mass., Nov. 6 Biopure Corporation,(Nasdaq: BPUR ... public,offering of stock and warrants that raised net ... exercise of the warrants. Biopure,sold 19,377,500 new shares ... an,additional 19,377,500 shares, including 2,527,500 shares and 2,527,500,warrants ...
... group says , TUESDAY, Nov. 6 (HealthDay News) -- Standard ... been proposed by a team of Johns Hopkins experts, who ... comparisons and help improve patient safety. , "Hospitals are ... this is long overdue, the data is only helpful if ...
... for patients with sudden, life-threatening attacks, trial shows , , ... kind of medication has failed as treatment for the ... trial finds. , The drug, tezosentan, did not improve ... or cut their risk of death after acute ...
Cached Medicine News:Health News:Thermage Announces Third Quarter Financial Results 2Health News:Thermage Announces Third Quarter Financial Results 3Health News:Thermage Announces Third Quarter Financial Results 4Health News:Thermage Announces Third Quarter Financial Results 5Health News:Thermage Announces Third Quarter Financial Results 6Health News:Thermage Announces Third Quarter Financial Results 7Health News:Thermage Announces Third Quarter Financial Results 8Health News:Thermage Announces Third Quarter Financial Results 9Health News:Sixteen Organizations Implement ACG Rx-PM Predictive Modeling from Johns Hopkins University, DST Health Solutions 2Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 2Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 3Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 4Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 5Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 6Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 7Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 8Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 9Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 10Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 11Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 12Health News:Experimental Drug Fails Against Heart Failure 2Health News:Experimental Drug Fails Against Heart Failure 3
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... industry is expecting a busy summer this year, and ... Day weekend, more hotels and resorts are raising their ... according George Clarke, CEO of UMF Corporation, a developer ... hotels and resorts adopting environmental hygiene practices developed for ...
... SAN FRANCISCO, May 22, 2012  Boehringer Ingelheim announced ... the investigational compound tiotropium delivered once-daily via the ... moderate persistent asthma. The data were presented at ... Society (ATS 2012). Boehringer Ingelheim announced that a ...
Cached Medicine Technology:With Busy Summer Forecast Ahead, More Hotels Are Raising Hygiene Standards, Says UMF Corporation 2Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 2Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 3Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 4
... latest in the Magnes line of biomagnetometer systems, ... full cortical coverage, provides the highest detector density ... of a wide range of neuronal activity. The ... detector configurations and can be equipped with radial ...
... for basic and advanced NCS, ... large 12.1" XGA (1024 x ... the latest in technology allow ... advanced NCS capabilities, advanced EMG ...
... is a non-invasive and painless method of ... Cadwell Laboratories manufactures two magnetic stimulation devices, ... Stimulator (HSMS). The Hight Speed MES-10 magnetic ... to 25 Hz at full power. Several ...
... are the latest innovation ... portable battery-powered EEG headboxes. ... new mechanical design, and ... standard MOBEE24plus and MOBEE32 ...
Medicine Products: